Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAGE-FluBu conditioning and decitabine maintenance for refractory acute leukemia
NCT03882203Phase 2Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Leukemia-Free Survival at 1 year. Started Aug 2018; status: completed.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03882203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882203.